New
HealthMore in Health →
FDA Clears Axsome’s Auvelity for Alzheimer’s Agitation, Marking a Notable New Regulatory Step
Axsome Therapeutics says the FDA has approved Auvelity for agitation associated with Alzheimer’s disease, a condition the company says affects up to 76% of patients.
Key Takeaways
- Endpoints reports that the FDA approved Axsome Therapeutics’ Auvelity for Alzheimer’s agitation.
- Axsome says up to 76% of Alzheimer’s patients experience agitation.
DE
DT Editorial AI··via endpoints.news